These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

595 related items for PubMed ID: 15734758

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
    Babayof R, Margalioth EJ, Huleihel M, Amash A, Zylber-Haran E, Gal M, Brooks B, Mimoni T, Eldar-Geva T.
    Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Exposure to human chorionic gonadotropin during in vitro maturation does not improve the maturation rate and developmental potential of immature oocytes from patients with polycystic ovary syndrome.
    Ge HS, Huang XF, Zhang W, Zhao JZ, Lin JJ, Zhou W.
    Fertil Steril; 2008 Jan; 89(1):98-103. PubMed ID: 17524398
    [Abstract] [Full Text] [Related]

  • 6. Vascular endothelial growth factor and its soluble receptor in patients with polycystic ovary syndrome undergoing IVF.
    Artini PG, Ruggiero M, Parisen Toldin MR, Monteleone P, Monti M, Cela V, Genazzani AR.
    Hum Fertil (Camb); 2009 Mar; 12(1):40-4. PubMed ID: 19330612
    [Abstract] [Full Text] [Related]

  • 7. The effects of 'coasting' on follicular fluid concentrations of vascular endothelial growth factor in women at risk of developing ovarian hyperstimulation syndrome.
    Tozer AJ, Iles RK, Iammarrone E, Gillott CM, Al-Shawaf T, Grudzinskas JG.
    Hum Reprod; 2004 Mar; 19(3):522-8. PubMed ID: 14998945
    [Abstract] [Full Text] [Related]

  • 8. The effect of low dose human chorionic gonadotropin on follicular response and oocyte maturation in PCOS patients undergoing IVF cycles: a randomized clinical trial of efficacy and safety.
    Ashrafi M, Kiani K, Ghasemi A, Rastegar F, Nabavi M.
    Arch Gynecol Obstet; 2011 Dec; 284(6):1431-8. PubMed ID: 21210134
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Homocysteine concentrations in follicular fluid are associated with poor oocyte and embryo qualities in polycystic ovary syndrome patients undergoing assisted reproduction.
    Berker B, Kaya C, Aytac R, Satiroglu H.
    Hum Reprod; 2009 Sep; 24(9):2293-302. PubMed ID: 19443458
    [Abstract] [Full Text] [Related]

  • 11. Follicular fluid levels of anti-Mullerian hormone as a predictor of oocyte maturation, fertilization rate, and embryonic development in patients with polycystic ovary syndrome.
    Mashiach R, Amit A, Hasson J, Amzalzg S, Almog B, Ben-Yosef D, Lessing JB, Limor R, Azem F.
    Fertil Steril; 2010 May 01; 93(7):2299-302. PubMed ID: 19261276
    [Abstract] [Full Text] [Related]

  • 12. Follicular aspiration during the selection phase prevents severe ovarian hyperstimulation in patients with polycystic ovary syndrome who are undergoing in vitro fertilization.
    Zhu WJ, Li XM, Chen XM, Zhang L.
    Eur J Obstet Gynecol Reprod Biol; 2005 Sep 01; 122(1):79-84. PubMed ID: 16154042
    [Abstract] [Full Text] [Related]

  • 13. Natural-cycle in vitro fertilization combined with in vitro maturation of immature oocytes is a potential approach in infertility treatment.
    Chian RC, Buckett WM, Abdul Jalil AK, Son WY, Sylvestre C, Rao D, Tan SL.
    Fertil Steril; 2004 Dec 01; 82(6):1675-8. PubMed ID: 15589878
    [Abstract] [Full Text] [Related]

  • 14. [Oocyte and embryo quality and outcome of ICSI cycles in patients with polycystic ovary syndrome (PCOS) versus normo-ovulatory].
    Kdous M, Chaker A, Zhioua A, Zhioua F.
    J Gynecol Obstet Biol Reprod (Paris); 2009 Apr 01; 38(2):133-43. PubMed ID: 19179017
    [Abstract] [Full Text] [Related]

  • 15. Differential regulation of VEGF after final oocyte maturation with GnRH agonist versus hCG: a rationale for OHSS reduction.
    Cerrillo M, Rodríguez S, Mayoral M, Pacheco A, Martínez-Salazar J, Garcia-Velasco JA.
    Fertil Steril; 2009 Apr 01; 91(4 Suppl):1526-8. PubMed ID: 18990367
    [Abstract] [Full Text] [Related]

  • 16. Relations between steroids and AMH: impact of basal and intrafollicular steroids to AMH ratios on oocyte yield and maturation rate in women with or without polycystic ovary undergoing in vitro fertilization.
    Hossein G, Arabzadeh S, Hossein-Rashidi B, Hosseini MA.
    Gynecol Endocrinol; 2012 Jun 01; 28(6):413-7. PubMed ID: 21992510
    [Abstract] [Full Text] [Related]

  • 17. Vascular endothelial growth factor and inhibin A in follicular fluid of infertile patients who underwent in vitro fertilization with a gonadotropin-releasing hormone antagonist.
    Cunha-Filho JS, Lemos N, Stein N, Laranjeira A, Passos EP.
    Fertil Steril; 2005 Apr 01; 83(4):902-7. PubMed ID: 15820798
    [Abstract] [Full Text] [Related]

  • 18. Prospective randomized study of human chorionic gonadotrophin priming before immature oocyte retrieval from unstimulated women with polycystic ovarian syndrome.
    Chian RC, Buckett WM, Tulandi T, Tan SL.
    Hum Reprod; 2000 Jan 01; 15(1):165-70. PubMed ID: 10611207
    [Abstract] [Full Text] [Related]

  • 19. Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer.
    Doldi N, Persico P, Di Sebastiano F, Marsiglio E, Ferrari A.
    Gynecol Endocrinol; 2006 May 01; 22(5):235-8. PubMed ID: 16785142
    [Abstract] [Full Text] [Related]

  • 20. Relationship of follicular fluid prorenin to oocyte maturation, steroid levels, and outcome of in vitro fertilization.
    Itskovitz J, Rubattu S, Rosenwaks Z, Liu HC, Sealey JE.
    J Clin Endocrinol Metab; 1991 Jan 01; 72(1):165-71. PubMed ID: 1986016
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.